Skip to main content
Premium Trial:

Request an Annual Quote

Victor Dzau

Premium
Alnylam Pharmaceuticals said this week that Victor Dzau has been elected to the company’s board of directors.
 
Dzau is currently chancellor for health affairs at Duke University, and president and CEO of the Duke University Health System. He is also a professor of medicine at the school.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.